CN112441825A - 用于缓解或改善炎症的陶瓷组合物及其制备方法 - Google Patents
用于缓解或改善炎症的陶瓷组合物及其制备方法 Download PDFInfo
- Publication number
- CN112441825A CN112441825A CN201911227121.9A CN201911227121A CN112441825A CN 112441825 A CN112441825 A CN 112441825A CN 201911227121 A CN201911227121 A CN 201911227121A CN 112441825 A CN112441825 A CN 112441825A
- Authority
- CN
- China
- Prior art keywords
- ceramic composition
- inflammation
- pulverized
- reducing
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 239000000919 ceramic Substances 0.000 title claims abstract description 78
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 67
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 28
- 229910052626 biotite Inorganic materials 0.000 claims abstract description 21
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 19
- 230000000638 stimulation Effects 0.000 claims abstract description 16
- 239000011435 rock Substances 0.000 claims abstract description 15
- 239000004575 stone Substances 0.000 claims abstract description 15
- 238000010298 pulverizing process Methods 0.000 claims description 34
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 26
- 238000010304 firing Methods 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 24
- 239000000463 material Substances 0.000 claims description 22
- 238000000465 moulding Methods 0.000 claims description 19
- 238000005498 polishing Methods 0.000 claims description 16
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 claims description 15
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 claims description 15
- 206010030113 Oedema Diseases 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 14
- 102000004889 Interleukin-6 Human genes 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 229940100601 interleukin-6 Drugs 0.000 claims description 13
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 206010003246 arthritis Diseases 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 229910052875 vesuvianite Inorganic materials 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 3
- 208000012659 Joint disease Diseases 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 210000000629 knee joint Anatomy 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000009256 patellar tendinitis Diseases 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 239000000047 product Substances 0.000 description 21
- 230000001939 inductive effect Effects 0.000 description 16
- 230000008569 process Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 7
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 229910052732 germanium Inorganic materials 0.000 description 4
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 229910052709 silver Inorganic materials 0.000 description 4
- 239000004332 silver Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000010946 fine silver Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000000015 thermotherapy Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 229910020175 SiOH Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- CHWRSCGUEQEHOH-UHFFFAOYSA-N potassium oxide Chemical compound [O-2].[K+].[K+] CHWRSCGUEQEHOH-UHFFFAOYSA-N 0.000 description 1
- 229910001950 potassium oxide Inorganic materials 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
- C04B35/16—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay
- C04B35/18—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics based on silicates other than clay rich in aluminium oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0624—Apparatus adapted for a specific treatment for eliminating microbes, germs, bacteria on or in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0625—Warming the body, e.g. hyperthermia treatment
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/628—Coating the powders or the macroscopic reinforcing agents
- C04B35/62802—Powder coating materials
- C04B35/62842—Metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
- A61N2005/066—Radiation therapy using light characterised by the wavelength of light used infrared far infrared
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/34—Non-metal oxides, non-metal mixed oxides, or salts thereof that form the non-metal oxides upon heating, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3427—Silicates other than clay, e.g. water glass
- C04B2235/3463—Alumino-silicates other than clay, e.g. mullite
- C04B2235/3472—Alkali metal alumino-silicates other than clay, e.g. spodumene, alkali feldspars such as albite or orthoclase, micas such as muscovite, zeolites such as natrolite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/34—Non-metal oxides, non-metal mixed oxides, or salts thereof that form the non-metal oxides upon heating, e.g. carbonates, nitrates, (oxy)hydroxides, chlorides
- C04B2235/3427—Silicates other than clay, e.g. water glass
- C04B2235/3463—Alumino-silicates other than clay, e.g. mullite
- C04B2235/3481—Alkaline earth metal alumino-silicates other than clay, e.g. cordierite, beryl, micas such as margarite, plagioclase feldspars such as anorthite, zeolites such as chabazite
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/40—Metallic constituents or additives not added as binding phase
- C04B2235/408—Noble metals
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/02—Composition of constituents of the starting material or of secondary phases of the final product
- C04B2235/30—Constituents and secondary phases not being of a fibrous nature
- C04B2235/42—Non metallic elements added as constituents or additives, e.g. sulfur, phosphor, selenium or tellurium
- C04B2235/422—Carbon
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/65—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes
- C04B2235/656—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes characterised by specific heating conditions during heat treatment
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B2235/00—Aspects relating to ceramic starting mixtures or sintered ceramic products
- C04B2235/65—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes
- C04B2235/656—Aspects relating to heat treatments of ceramic bodies such as green ceramics or pre-sintered ceramics, e.g. burning, sintering or melting processes characterised by specific heating conditions during heat treatment
- C04B2235/6567—Treatment time
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Inorganic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及用于缓解或改善炎症的陶瓷组合物及其制备方法,更详细地,涉及作为包含麦饭石、火山灰、黑云母、碳及火山石的陶瓷组合物,通过温热刺激缓解及改善炎症的陶瓷组合物及其制备方法。
Description
技术领域
本发明涉及用于缓解或改善炎症的陶瓷组合物,更详细地,涉及包含麦饭石、火山灰、黑云母、碳及火山石的用于缓解或改善炎症的陶瓷组合物及其制备方法。
背景技术
日常生活中发生的免疫反应是在人体内部发生的生理保护活动,而炎症是可以通过我们的肉眼确认的免疫反应之一。炎症会引起发烧症状、血管舒张及肿胀等多种可见的生理现象,当被炎症反应介质促进时,使血管的舒张及血管通透性增加,并且收集具有吞噬作用的颗粒细胞、树突细胞及B细胞等并激活它们。当炎症反应开始时,细胞因子(cytokine)会过量分泌,从而引起与炎症相关的疾病,并且由炎症性细胞因子表达的诱导型一氧化氮合酶(iNOS)促进氧化一氮(NO,nitric oxide)的生成。
炎症性疾病是全世界主要的死亡原因之一。炎症性疾病影响各种器官及组织,例如,血管、心脏、大脑、神经、关节、皮肤、肺、眼睛、胃肠道、肾脏、甲状腺、肾上腺、胰腺、肝及肌肉。炎症性疾病的治疗成为制药公司和研究人员的关注对象。尽管最近在该领域进行了许多研究,且当前用于炎症性疾病的疗法包括用非特异性药物缓解症状以及减少炎症、延缓疾病的发展等,但这些疗法具有药物副作用及耐性等的严重问题。
当根据波长细分红外线区域时,远红外线是指距可见光最远的电磁波。与远红外线有关的医学疗法虽然是未明确鉴定的方式,但据报告对高血压或心力衰竭或类风湿性关节炎等慢性疾病具有治疗效果。并且,远红外线不像可见光或近红外线,不被活体吸收并被反射,而是被活体吸收且借助渗透力渗透到活体内以产生自发热,从而不仅带来温热效果及出汗效果,吸收到活体内的远红外线还促进新陈代谢,改善血液循环,恢复酶的生成并激活衰老细胞,从而促进废物和多余脂肪的排泄,抑制导致疲劳或衰老的乳酸、游离脂肪酸、脂肪酸脂、胆固醇、过量的盐及尿酸的生成,保持健康年轻。
当显示出如上所述的效果的远红外线与温热治疗结合使用时,作为缓解肌肉痛、关节炎、及由此产生的疼痛的方案公开了房屋形状或带状产品。
与此相关地,韩国专利授权第10-1332563号公开了通过天然火山灰的红外线放射试验及阴离子产生实验和对诱导炎症的动物涂敷天然火山灰来确认作为抗炎效果的环氧合酶-2(COX-2)抑制效果、诱导型一氧化氮合酶(iNOS)抑制效果、细胞因子(cytokine)抑制效果。并且,韩国专利授权第10-1720745号公开了使用木炭可以获得远红外线放射效果,通过外红外辐射热和远红外线来渗透到使用者的体内,以帮助疲劳恢复和血液循环。然而,尚不清楚包含麦饭石、火山灰、黑云母、碳及火山石的陶瓷组合物,并且其用于缓解或改善炎症的用途也是未知的。
现有技术文献
专利文献
韩国专利授权第10-1332563号
韩国专利授权第10-1809090号
韩国专利授权第10-1720745号
非专利文献
Yang yeseok,热疗对缓解下半身浮肿及疼痛的影响,建国大学硕士学位论文,2017
发明内容
技术问题
本发明的目的在于,提供包含麦饭石、火山灰、黑云母、碳及火山石且具有缓解及改善炎症效果的陶瓷组合物。
并且,提供上述陶瓷组合物的制备方法及包含上述陶瓷组合物作为有效成分的饰品、医疗设备、热垫及药学组合物。
解决问题的手段
为了实现上述目的,本发明通过提供包含麦饭石、火山灰、黑云母、碳及火山石的用于缓解或改善炎症的陶瓷组合物来实现。
在本发明的一实施方式中,上述陶瓷组合物包含麦饭石、火山灰、黑云母、碳及火山石,根据更优选特征,包含100重量份的麦饭石、0.5重量份至1.5重量份的火山石、0.05重量份至0.15重量份的碳、1重量份至3重量份的火山灰及0.5重量份至1.5重量份的黑云母。
并且,本发明具有缓解或改善炎症的效果,并且具有减少诱导型一氧化氮合酶(iNOS)、减少一氧化氮及减少白细胞介素-6(IL-6)的效果。
并且,在本发明的一实施方式中,上述炎症可以是浮肿。
并且,在本发明的一实施方式中,上述浮肿可由关节炎引起,具体地,可由骨关节炎、类风湿性关节炎、痛风、强直性脊柱炎、膝关节障碍、化脓性关节炎及髌肌腱炎引起。
并且,在本发明的一实施方式中,上述缓解或改善炎症通过如下的方法实现:将上述陶瓷组合物加热至35℃至40℃的温度,用加热的陶瓷组合物温热刺激炎症部位,每次进行40分钟至80分钟。并且,在本发明的一实施方式中,温热刺激以每周4次至6次的频率进行3周至5周。更具体地,温热刺激通过如下的方法实现:将陶瓷组合物加热至38℃的温度,用加热的陶瓷组合物温热刺激炎症部位60分钟,能够以每周5次的频率进行4周。
本发明还提供用于缓解或改善炎症的陶瓷组合物的制备方法,其特征在于,包括:原料粉碎步骤,分别粉碎选自由麦饭石、火山灰、黑云母、碳及火山石组成的组中的一种以上矿物;微粉碎步骤,将分别通过上述原料粉碎步骤粉碎的粉碎物混合,并加入水后进行微粉碎;空气注入步骤,注入空气,以使通过上述微粉碎步骤微粉碎的粉碎物具有颗粒形状;成型步骤,将通过上述空气注入步骤具有颗粒形状的微粉碎物放入模具并进行加压成型;烧成步骤,对通过上述成型步骤成型的成型物进行烧成;以及研磨步骤,对通过上述烧成步骤烧成的成型物的表面进行研磨。
并且,在本发明的一实施方式中,还提供在上述微粉碎步骤与上述空气注入步骤之间还进行用银纳米微粒子对通过上述微粉碎步骤微粉碎的粉碎物进行涂敷的步骤。
并且,在本发明的一实施方式中,在上述微粉碎步骤中,将分别通过上述原料粉碎步骤粉碎的粉碎物混合来制备混合物,在100重量份的上述混合物中加入60重量份至80重量份的溶剂后,粉碎成1000目至3000目的大小。
并且,在本发明的一实施方式中,在上述烧成步骤中,将通过上述成型步骤成型的成型物在900℃至1200℃的温度下烧成10小时至24小时。
并且,为了实现上述目的,本发明提供包含用于缓解或改善炎症的陶瓷组合物的饰品、医疗设备、热垫及药学组合物。
发明的效果
根据本发明的包含麦饭石、火山灰、黑云母、碳及火山石的陶瓷组合物可以放射大量的远红外线,由此可以直接或间接地温热刺激生物体,从而具有根本上缓解及改善炎症的卓越效果。
附图说明
图1为示出通过蛋白质印迹(Western blot)分析由本发明的实验例1-2处理的巨噬细胞的诱导型一氧化氮合酶(iNOS)蛋白的图表。(NDC:陶瓷组合物)
图2为示出通过一氧化氮测定方法分析由本发明的实验例1-3处理的巨噬细胞的一氧化氮的合成量的图表。
图3为示出测量由本发明的实验例3处理的实验组、关节炎诱导组的血液中白细胞介素-6(IL-6)的浓度的图表。
图4为示出用于观察浮肿缓解程度的重危评分(Severity score)标准的图。
图5为示出通过陶瓷组合物刺激的实验组和炎症诱导组的重危评分(Severityscore)的平均值的图表。
图6至图7为示出在本发明的实验例2-2中使用的陶瓷组合物、应用上述陶瓷组合物的远红外线照射装置及温热刺激过程的照片。
图8为示出使用在本发明的实验例2-2中使用的陶瓷组合物的温热刺激过程的示意图。
图9为示出根据制备例1制备的陶瓷组合物的图。
具体实施方式
以下,将详细说明本发明的优选实施例和各成分的物理性质,其旨在充分详细地解释以使本领域普通技术人员能够容易地实施本发明,这并不意味着限制本发明的技术思想及范围。
并且,制备过程包括可以在本领域技术人员显而易见的范围内改变的范围。
根据本发明的用于缓解或改善炎症的陶瓷组合物是指包含麦饭石、火山灰、黑云母、碳及火山石的陶瓷组合物。
具体地,上述陶瓷组合物由100重量份的麦饭石、1重量份至3重量份的火山灰、0.5重量份至1.5重量份的黑云母、0.05重量份至0.15重量份的碳及0.5重量份至1.5重量份的火山石组成。
上述陶瓷组合物通过温热刺激实现对炎症的缓解或改善,温热刺激方法如下:将炎症的产生部位介于陶瓷组合物后,以35℃至40℃的温度加热陶瓷组合物,用加热的陶瓷组合物温热刺激炎症部位,每次40分钟至80分钟。并且,温热刺激能够以每周4次至6次的频率进行3周至5周。
在此情况下,对于上述温热刺激的条件,最佳条件为每次以38℃的温度进行60分钟,且以每周5次的频率进行4周。
上述麦饭石是由每立方厘米(cm3)约有3万个至15万个孔形成的超多孔质原石,具有非常强的吸附力,作为包含约25000多种无机盐类的矿物,并且显示出加热时会发出大量的远红外线的特征。
并且,上述火山灰(pozzolan)指火山灰、硅藻土、凝灰岩、硅质二氧化硅等,其作为一种蜡石,在5μm至20μm波长中放射出90%至97%远红外线。
并且,与黄土、麦饭石相比,上述黑云母是具有约3倍以上的远红外线放射率且含有大量锗的矿物,并且上述黑云母指由硅酸酐(SiO2)、氧化铝(Al2O3)、氧化铁(Fe2O3)、氧化亚铁(FeO)、氧化镁(MgO)、氧化钾(K2O)、水(H2O)及其他细金属组成的黑云母。在本发明中,黑云母可以是包含锗的黑云母,可以包含10ppm以上含量的锗。由于锗在陶瓷形成过程中被氧化,其远红外线放射率及放射能量与磷剂的放射能量相似,因此远红外线波长使人体的吸收更容易。
上述火山石仅由纯无机物组成,因此不仅包含各种必需的矿物成分,而且还显示出放射高远红外线的特征。
由上述成分组成的陶瓷组合物由如下的步骤制备而成:原料粉碎步骤,分别粉碎麦饭石、火山石、碳、火山灰及黑云母;微粉碎步骤,将分别通过上述原料粉碎步骤粉碎的粉碎物混合,并加入水后进行微粉碎;空气注入步骤,注入空气,以使通过上述微粉碎步骤微粉碎的粉碎物具有颗粒形状;成型步骤,将通过上述空气注入步骤具有颗粒形状的微粉碎物放入模具并进行加压成型;烧成步骤,对上述成型步骤成型的成型物进行烧成;以及研磨步骤,对通过上述烧成步骤烧成的成型物的表面进行研磨。
上述原料粉碎步骤是将麦饭石、火山灰、黑云母、碳及火山石分别以350目至700目的大小粉碎的步骤,若通过上述原料粉碎步骤粉碎的原料的粒子大小小于350目,则因粒子大小过大而使通过上述微粉碎步骤微粉碎的过程难以进行,若通过上述原料粉碎步骤粉碎的原料的粒子大小大于700目,则通过上述微粉碎步骤微粉碎的过程的效率会有所提高,但因粉碎工程的时间过长而有可能导致生产性降低。
上述微粉碎步骤由如下的过程组成:以如上所述的含量范围混合分别通过上述原料粉碎步骤粉碎的粉碎物,相对于100重量份的上述混合物混合60重量份至80重量份的溶剂后,使用球磨机将其微粉碎至1000目至3000目的粒子大小。溶剂用于溶解粉碎物并使其具有颗粒形状,可以使用水,但不限于此。
在此情况下,若通过上述过程微粉碎的粉碎物的粒子大小小于1000目,则因成型后产品的表面粗糙而不美观,若粉碎物的粒子大小大于3000目,则会降低生产性。
上述空气注入步骤是注入空气以使通过上述微粉碎步骤微粉碎的粉碎物呈颗粒形状的步骤,并且是使用喷雾干燥机注入空气以使通过上述微粉碎步骤微粉碎的粉碎物呈颗粒形状的步骤。
在上述过程中,使用喷雾干燥机注入空气以具有颗粒形状是为了防止在上述成型步骤中所进行的加压过程中对产品产生裂纹及裂缝。
上述成型步骤是将通过上述空气注入步骤具有颗粒形状的微粉碎物放入模具并进行加压成型的步骤,其由将通过上述空气注入步骤具有颗粒形状的微粉碎物放入模具并进行加压成型的过程实现,上述加压成型是制造所要制造的形状的模具并将呈颗粒形状的粉末填充到油空压机后,按照产品的种类施加响应压力来成型的过程。在此情况下,如果可以原样使用上述颗粒形状的微粉碎物,则也可以重新粉化使用。
上述烧成步骤是对通过上述成型步骤成型的成型物进行烧成的步骤,其由对通过上述成型步骤成型的成型物以900℃至1200℃的温度进行10小时至24小时的烧成的过程实现。
在上述烧成步骤中,若烧成温度低于900℃,则因烧成不能完全进行而降低成型物的外观品质,若上述烧成温度高于1200℃,则会降低成型品的机械物性。并且,在上述烧成步骤中,若烧成时间小于10小时,则不能完全烧成,若在上述烧成步骤中,烧成时间大于24小时,则会降低生产性。
上述研磨步骤是对通过上述烧成步骤烧成的成型物的表面进行研磨的步骤,其由如下的过程实现:当完成由如上所述的温度及时间进行的烧成步骤时,自然冷却所烧成的成型物,并对自然冷却的成型物的表面进行研磨。
上述研磨步骤由通过将切割石放入震动抛光机或离心抛光机来切割上述成型物的表面后进行研磨的过程实现,在此情况下,切割时间平均为20小时至30小时左右。
并且,在经如上所述的时间的切割过程后,将其表面被切割的成型物放入抛光研磨机,并放入抛光石及抛光用化合物进行抛光研磨。
在如上所述地以两个步骤进行切割及研磨的情况下,当将陶瓷组合物用作项链、手链等的医疗设备时,因其外观美观而商品性得到提高。在制造出通过如上所述的过程放射远红外线的陶瓷组合物,将其以适当的大小和重量牢固包装并销售,其可应用于电热垫、热疗设备、腰带、坐垫、枕头、手链及项链等的医疗设备及饰品。
并且,在上述微粉碎步骤与上述空气注入步骤之间还可以进行用银纳米微粒子对通过上述微粉碎步骤微粉碎的粉碎物进行涂敷的步骤。若用银纳米微粒子涂敷上述微粉碎的粉碎物,则远红外线陶瓷组合物的抗菌性大大提高。
在此情况下,在对上述微粉碎的粉碎物涂敷银纳米微粒子的过程中,通过混合表面活性剂和硝酸银来制备混合溶液。在此情况下,阳离子、阴离子、非离子表面活性剂均可用作上述表面活性剂。而且,当将溶解有硼酸钠的水溶液作为还原剂加入到上述混合溶液时,在溶解的银粒子还原的过程中,上述混合溶液的颜色从无色渐渐变为深棕色并生成银微粒子。在此情况下,所加入的表面活性剂阻碍银微粒子的生长,从而获得银纳米粒子分散在水溶液中的胶体。而且,为了去除如上所述的银微粒子的生成后未反应的物质及杂质,以5000rpm至8000rpm的速度离心分离,则所生成的银纳米微粒子分离为银纳米微粒子及溶液,弃去上清液并重复洗涤三次,来最终制备借助表面活性剂稳定的银胶体。为了获得如此制备的银纳米微粒子均匀分散的粉末,向上述微粉碎的粉碎物加入0.5%的盐酸(HCl)或氢氟酸(HF)溶液并进行酸处理,将其与稳定的银胶体混合并搅拌,则生成涂敷有纳米微粒子的微粉碎物,可以通过使用喷雾干燥机注入空气以使其呈颗粒形状的方式进行干燥来使用。
在此情况下,上述酸处理是因为若进行酸处理,则在上述微粉碎的粉碎物的表面生成多个硅烷醇基(SiOH),并且去除了杂质,因此可以使银纳米微粒子容易地固定。在此情况下,上述微粉碎的粉碎物与银胶体的混合比例为100:0.1重量份至100:0.4重量份,但不限于此。
上述陶瓷组合物具有缓解或改善炎症的用途,炎症是对因损伤、感染或免疫系统而被识别为外来物质的分子的体内反应,成为陶瓷组合物的缓解或改善炎症的对象的疾病包括慢性炎性疾病、急性炎性疾病。具体地,慢性炎性疾病包括白塞病(Behcet’sdisease)、克罗恩病(Crohn’s disease)、类风湿性关节炎(rheumatoid arthritis)、毛囊、脂漏性皮肤炎、银屑病等。但不限于上述疾病种类。更具体地,作为缓解或改善炎症的效果,可以通过减少诱导型一氧化氮合酶(iNOS)蛋白、一氧化氮及白细胞介素-6(IL-6)来缓解或改善炎性疾病。
上述炎症可以是浮肿。并且,上述浮肿可由关节炎引起,具体地,可由骨关节炎、类风湿性关节炎、痛风、强直性脊柱炎、膝关节障碍、化脓性关节炎及髌肌腱炎引起。
上述陶瓷组合物或涂敷有银纳米粒子的陶瓷组合物可用作医疗设备、饰品、热垫及药学组合物。作为医疗设备可以用作低频治疗设备、远红外线治疗设备、热敷及冷敷设备、按摩设备、拔罐设备、矫正器、轮椅及护具。并且,作为饰品,具体可以用作手链、项链、戒指、手镯、吊坠、脚链、胸针、手表、袖扣、发夹、发箍、腰带、吊带、眼镜架及领带夹。
包含陶瓷组合物的药学组合物以单独的方式或与药剂学活性物质结合或集合使用,并包含药剂学上可接受的量的陶瓷组合物。药剂学活性物质是指与药剂学领域中通常可接受的载体配合使用的物质,可以按照口服给药、涂敷方式、赋形剂等制剂。更具体地,可用作药剂学活性物质的形态为乳糖、葡萄糖、蔗糖、山梨糖醇、淀粉、透明质酸、甘油、丙二醇、聚乙二醇等。
以下,将参照实验例说明根据本发明的通过陶瓷组合物缓解及改善炎症的效果。但是,本发明不限于以下的制备例及实验例。
制备例1:陶瓷组合物的制备
以350目至700目的大小分别粉碎麦饭石、火山石、碳、火山灰及黑云母,通过混合分别粉碎的95.9kg的麦饭石、1kg的火山石、0.1kg的碳、2kg的火山灰及1kg的黑云母来制备混合物,将70kg的水与100kg的上述混合物混合,使用球磨机粉碎成1000目至3000目的粒子大小后,用喷雾干燥机向通过上述过程粉碎的粉碎物注入空气来制粒,将制粒的粉碎物放入模具并压缩成型,将烧成压缩成形的成型物在1050℃的温度下烧成17小时,切割烧成的成型物后,放入抛光研磨机,加入抛光石及抛光用化合物并通过抛光研磨过程制备了放射远红外线的陶瓷组合物。
实验例1:在Raw 264.7细胞(cell)中的陶瓷组合物的抗炎作用的评估
实验例1-1:Raw 264.7细胞的培养及LPS处理
为了观察免疫反应,在培养箱(incubator)中培养了Raw 264.7细胞(37℃、5%的CO2)。细胞培养分为对照组、炎症诱导组、放射远红外线的陶瓷组合物及低强度超声波刺激组。为了诱导炎症,以1μg/mL的浓度处理了脂多糖(LPS,Lipopolysaccharide)。放射远红外线的陶瓷组合物是在培养箱内相应细胞培养皿(Cell culture dish)上、下放置通过上述制备例1制备的方式远红外线的陶瓷组合物来进行培养。
实验例1-2:观察通过蛋白质印迹(Western blot)的诱导型一氧化氮合酶
将通过蛋白质印迹(Western blot)分析由本发明的实验例1处理的巨噬细胞(Raw264.7cell)的诱导型一氧化氮合酶蛋白示于图1。如图1所示,可知,与炎症诱导组(RA)相比,由通过本发明的陶瓷组合物刺激的实验组(RA+NDC)的诱导型一氧化氮合酶蛋白的表达明显减少。
实验例1-3:观察通过一氧化氮检测的一氧化氮的合成量
将通过一氧化氮测定方法分析由本发明的实验例1处理的巨噬细胞(Raw264.7cell)的一氧化氮的合成量示于图2。
一氧化氮的测量使用了一氧化氮测定方法,上述一氧化氮测定方法使用格里斯试剂(Griess reagent),该测定方法是如下的方法:将样品(Sample)离心后,分别分离100μL的上清液,并在常温下,将100μL的格里斯试剂(Griess reagent)在96孔板(well plate)上反应10分钟后,以595nm的波长测定吸光度。
如以下图2所示,可知,与炎症诱导组(RA)相比,由通过本发明的陶瓷组合物刺激的实验组(RA+NDC)的一氧化氮的合成量明显降低。
实验例2:对小动物诱导及温热刺激类风湿性关节炎的方法
实验例2-1:实验组、炎症诱导组及对照组的设定
给实验大鼠(C57BL6、雄性、8周龄)提供基本饮食(固体饲料,Cargill AgriPurina股份有限公司,群山,韩国/自由饮水)一星期和适应环境后,每组配置10只,以使各组具有类似的平均体重。
实验组(RA+NDC):向10只8周龄雄性大鼠(C57BL6)的足底分别注射0.05mL的关节炎诱导物质以诱导关节炎,上述关节炎诱导物质是通过将弗氏完全佐剂(CFA,CompleteFreund's Adjuvant)与生理盐水以1:1的重量比混合而成,在从诱导关节炎的时间经过一周后,对陶瓷组合物进行温热刺激。
炎症诱导组(RA):向10只8周龄雄性大鼠(C57BL6)的足底分别注射0.05mL的关节炎诱导物质以诱导关节炎,上述关节炎诱导物质是通过将弗氏完全佐剂(CFA,CompleteFreund's Adjuvant)与生理盐水以1:1的重量比混合而成,从诱导关节炎的时间开始放置5周。
实验例2-2:对实验组进行温热刺激的方法
使用应用了陶瓷组合物的垫,每天在垫上进行38℃的温热刺激,每次1小时,每周5次,进行了4周,即,4周内共进行了20小时的基于陶瓷组合物的刺激。
实验例3:在诱导类风湿性关节炎的小动物中的血液中白细胞介素-6的浓度的观察
通过测量上述实验例2的实验组(RA+NDC)、炎症诱导组(RA)的血液中白细胞介素-6的浓度来以平均值示于图3。
实验组(RA+NDC)及炎症诱导组(RA)的血液中白细胞介素-6的浓度是在实验结束时(陶瓷组合物刺激4周后)从实验组和对照组的心脏采血,用乙二胺四乙酸微型容器(EDTAmicro-tainer)(BD biosciences,美国)仅分离血清以用作样品,使用小鼠白细胞介素-6ELISA试剂盒(Mouse IL-6ELISA Kit)通过酶免疫法(mouse enzyme-linkedimmunosorbent assay[ELISA]kits,ab100712,Abcam,San Francisco,CA,美国)定量小鼠血清内白细胞介素-6。
实验方法是根据制造商(Abcam)的ELISA说明书进行,其结果如下图3所示,可知,与炎症诱导组(RA)相比,实验组(RA+NDC)的白细胞介素-6的浓度明显减少。
实验例4:在诱导类风湿性关节炎的小动物中的重危评分(Severity score)的测定
实验例4-1:重危评分的测定法
通过重危评分表观察了上述实验例2的实验组、炎症诱导组的浮肿缓解程度,重危评分是按照显示在实验大鼠的症状来分类的,其细分为“红色(redness):1、红色加轻度浮肿(redness plus mild swelling):2、重度浮肿(severe swelling):3、关节畸形(jointdeformity):4’,如图4所示。通过分类各10只雄性大鼠的症状来测量重危评分以求出平均值。
实验结果4-2:重危评分结果
炎症诱导组及实验组中各10只的重危评分如表1所示,炎症诱导组的平均重危评分为2.8,实验组的平均重危评分为1.5。与平均重危评分有关的值示于图5。从实验组的平均重危评分的值非常低可以看出对由陶瓷组合物刺激的实验组具有缓解浮肿的效果。
表1炎症诱导组及实验组10只雄性大鼠的重危评分
因此,根据本发明的陶瓷组合物通过包含麦饭石、火山灰、黑云母、碳及火山石来放射大量远红外线从而减少诱导型一氧化氮合酶蛋白的表达,明显减少白细胞介素-6的浓度,且缓解浮肿,从而确认了根本上缓解及改善炎症或浮肿的效果。
Claims (17)
1.一种用于缓解或改善炎症的陶瓷组合物,其特征在于,包含麦饭石、火山灰、黑云母、碳及火山石。
2.根据权利要求1所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述陶瓷组合物包含100重量份的麦饭石、0.5重量份至1.5重量份的火山石、0.05重量份至0.15重量份的碳、1重量份至3重量份的火山灰及0.5重量份至1.5重量份的黑云母。
3.根据权利要求1所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述炎症为浮肿。
4.根据权利要求3所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述浮肿是由关节炎引起的炎症。
5.根据权利要求3所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述浮肿是由骨关节炎、类风湿性关节炎、痛风、强直性脊柱炎、膝关节障碍、化脓性关节炎及髌肌腱炎引起的炎症。
6.根据权利要求1所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述缓解或改善炎症通过如下的方法实现:将上述陶瓷组合物加热至35℃至40℃的温度,用加热的陶瓷组合物温热刺激炎症部位,每次进行40分钟至80分钟。
7.根据权利要求6所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述温热刺激以每周4次至6次的频率进行3周至5周。
8.根据权利要求6所述的用于缓解或改善炎症的陶瓷组合物,其特征在于,上述缓解或改善炎症通过如下的方法实现:将上述陶瓷组合物加热至38℃的温度,用加热的陶瓷组合物温热刺激炎症部位,温热刺激以每次60分钟、每周5次的频率进行4周。
9.一种用于缓解或改善炎症的陶瓷组合物的制备方法,其特征在于,包括:
原料粉碎步骤,分别粉碎选自由麦饭石、火山灰、黑云母、碳及火山石组成的组中的一种以上矿物;
微粉碎步骤,将分别通过上述原料粉碎步骤粉碎的粉碎物混合,并加入水后进行微粉碎;
空气注入步骤,注入空气,以使通过上述微粉碎步骤微粉碎的粉碎物具有颗粒形状;
成型步骤,将通过上述空气注入步骤具有颗粒形状的微粉碎物放入模具并进行加压成型;
烧成步骤,对通过上述成型步骤成型的成型物进行烧成;以及
研磨步骤,对通过上述烧成步骤烧成的成型物的表面进行研磨。
10.根据权利要求9所述的用于缓解或改善炎症的陶瓷组合物的制备方法,其特征在于,在上述微粉碎步骤与上述空气注入步骤之间还进行用银纳米微粒子对通过上述微粉碎步骤微粉碎的粉碎物进行涂敷的步骤。
11.根据权利要求9所述的用于缓解或改善炎症的陶瓷组合物的制备方法,其特征在于,在上述微粉碎步骤中,将分别通过上述原料粉碎步骤粉碎的粉碎物混合来制备混合物,在100重量份的上述混合物中加入60重量份至80重量份的水后,粉碎成1000目至3000目的大小。
12.根据权利要求9所述的用于缓解或改善炎症的陶瓷组合物的制备方法,其特征在于,在上述烧成步骤中,将通过上述成型步骤成型的成型物在900℃至1200℃的温度下烧成10小时至24小时。
13.一种饰品,其特征在于,包含根据权利要求1至8中任一项所述的用于缓解或改善炎症的陶瓷组合物。
14.一种医疗设备,其特征在于,包含根据权利要求1至8中任一项所述的用于缓解或改善炎症的陶瓷组合物。
15.一种热垫,其特征在于,包含根据权利要求1至8中任一项所述的用于缓解或改善炎症的陶瓷组合物。
16.一种抗炎药学组合物,其特征在于,包含根据权利要求1至8中任一项所述的用于缓解或改善炎症的陶瓷组合物。
17.根据权利要求16所述的抗炎药学组合物,其特征在于,上述抗炎药学组合物具有减少诱导型一氧化氮合酶、减少一氧化氮及减少白细胞介素-6的效果。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190106019A KR102339099B1 (ko) | 2019-08-28 | 2019-08-28 | 부종 완화 또는 개선용 세라믹 조성물(ndc) 및 이의 제조방법 |
KR10-2019-0106032 | 2019-08-28 | ||
KR10-2019-0106019 | 2019-08-28 | ||
KR1020190106032A KR102339100B1 (ko) | 2019-08-28 | 2019-08-28 | 염증 완화 또는 개선용 세라믹 조성물(ndc) 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112441825A true CN112441825A (zh) | 2021-03-05 |
Family
ID=74733119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911227121.9A Pending CN112441825A (zh) | 2019-08-28 | 2019-12-04 | 用于缓解或改善炎症的陶瓷组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112441825A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101182215A (zh) * | 2007-10-31 | 2008-05-21 | 青岛丽可医疗器械有限公司 | 一种医疗器械用生物化工陶瓷及其制备方法 |
KR101332563B1 (ko) * | 2012-09-06 | 2013-11-25 | 한림대학교 산학협력단 | 포졸란을 포함하는 항염증성 약학 조성물 |
KR101720745B1 (ko) * | 2015-11-02 | 2017-03-28 | 전병오 | 숯과 자석을 이용한 전열 매트 |
CN107056265A (zh) * | 2017-04-28 | 2017-08-18 | 青岛高智高新科技有限公司 | 一种远红外线陶瓷材料 |
WO2019108049A2 (ko) * | 2017-12-01 | 2019-06-06 | (주)카데시인코퍼레이션 | 미네랄 이온 혼합물을 포함하는 항암용, 항균용, 알콜분해용, 피부상처 치유, 피부재생용 또는 항천식용 조성물 |
-
2019
- 2019-12-04 CN CN201911227121.9A patent/CN112441825A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101182215A (zh) * | 2007-10-31 | 2008-05-21 | 青岛丽可医疗器械有限公司 | 一种医疗器械用生物化工陶瓷及其制备方法 |
KR101332563B1 (ko) * | 2012-09-06 | 2013-11-25 | 한림대학교 산학협력단 | 포졸란을 포함하는 항염증성 약학 조성물 |
KR101720745B1 (ko) * | 2015-11-02 | 2017-03-28 | 전병오 | 숯과 자석을 이용한 전열 매트 |
CN107056265A (zh) * | 2017-04-28 | 2017-08-18 | 青岛高智高新科技有限公司 | 一种远红外线陶瓷材料 |
WO2019108049A2 (ko) * | 2017-12-01 | 2019-06-06 | (주)카데시인코퍼레이션 | 미네랄 이온 혼합물을 포함하는 항암용, 항균용, 알콜분해용, 피부상처 치유, 피부재생용 또는 항천식용 조성물 |
Non-Patent Citations (1)
Title |
---|
何清湖: "《实用临床中药手册》", 31 December 2016, 湖南科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100907656B1 (ko) | 의료기기용 바이오 세라믹의 제조방법. | |
KR101602798B1 (ko) | 토르마늄을 유효성분으로 함유하는 항알레르기 효과를 갖는 조성물 | |
CN112811915B (zh) | 一种功能性材料及其制备方法 | |
CN112439132B (zh) | 使用陶瓷组合物和低强度超声波改善关节炎的装置 | |
JPH09173479A (ja) | 遠赤外線放射体およびそれを用いた医薬品ならびに食品 | |
CN112441825A (zh) | 用于缓解或改善炎症的陶瓷组合物及其制备方法 | |
KR102339100B1 (ko) | 염증 완화 또는 개선용 세라믹 조성물(ndc) 및 이의 제조방법 | |
CN101182215A (zh) | 一种医疗器械用生物化工陶瓷及其制备方法 | |
KR20190068304A (ko) | 제주 화산 송이를 이용한 허리벨트 | |
KR102339099B1 (ko) | 부종 완화 또는 개선용 세라믹 조성물(ndc) 및 이의 제조방법 | |
CN112516165B (zh) | 用于预防、治疗或改善糖尿病的陶瓷组合物及其制备方法 | |
KR102297627B1 (ko) | 원적외선 방출 세라믹 조성물(ndc)과 초음파를 이용한 염증 완화 및 개선용 장치 | |
CN108563036B (zh) | 一种伊利石六环石纳米负离子远红外保健眼镜框架及眼镜 | |
KR102025169B1 (ko) | 수용화 옥 추출물 제조 방법 및 화장료 조성물 | |
CN103125798A (zh) | 一种蜂王浆枸杞杏仁含片及其制备方法 | |
CN101306224B (zh) | 一种利用阳起石制取生殖健康用品的方法 | |
CN104759035A (zh) | 一种利用兹阳石制做保健用品的方法 | |
KR102339101B1 (ko) | 당뇨병 예방, 치료 또는 개선을 위한 세라믹 조성물(ndc) 및 이의 제조방법 | |
KR0129551B1 (ko) | 연옥분이 함유된 피부 첩부제(貼付劑) | |
KR0185501B1 (ko) | 다용도 광석분 | |
KR0185500B1 (ko) | 다용도 광석분 | |
KR0185504B1 (ko) | 다용도 광석분 | |
CN102309526A (zh) | 一种治疗烧烫伤的中药软膏剂及其加工方法 | |
TW201000166A (en) | Manufacturing method of energy stone | |
KR0185506B1 (ko) | 다용도 광석분 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |